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Abstract
Background: High levels of circulating advanced glyca-
tion end products (AGEs) can initiate chronic low-grade 
activation of the immune system (CLAIS) with each of 
these factors independently associated with cardiovascu-
lar (CV) morbidity and mortality. Therefore, our objective 
was to characterize the relationship between serum AGEs, 
CLAIS and other risk factors for CV disease in normoten-
sive non-diabetic individuals.
Methods: We measured body mass index (BMI), waist-
to-hip ratio (WHR), blood pressure, lipid and glucose 
profile in 44 non-diabetic volunteers (17 female, 27 males). 
Carbo xymethyl-lysine (CML) was measured by ELISA as a 
marker for circulating AGEs and NF-κB p65 activity as an 
inflammatory marker by DNA-binding in peripheral blood 
mononuclear cells lysates (PBMC).
Results: Plasma CML concentrations were related to dias-
tolic blood pressure (r = −0.51, p < 0.01) independently of 
age, sex, BMI and WHR (p < 0.05). Diastolic blood pressure 
was also related to NF-κB activity in PBMC (r = 0.47, p < 0.01) 
before and after adjustment for age, sex, BMI and WHR 
(p < 0.05). Plasma CML concentrations were related to the 
pulse pressure before (r = 0.42; p < 0.05) and after adjust-
ment for age, sex, BMI and waist (p < 0.05). Neither CML 
nor NF-κB activity were related to systolic blood pressure 
(both p = ns). Plasma CML concentrations were not asso-
ciated with plasma lipid or glucose concentrations (all 
p = ns).
Conclusions: Plasma AGE levels and NF-κB activity in 
PBMC were independent determinants of diastolic and 
pulse pressure in healthy normotensive individuals. 
This association suggests a role for AGEs in the etiology 
of hypertension, possibly via the initiation of CLAIS and 
aortic stiffening.
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Introduction
Cardiovascular disease (CVD) is one of the leading causes 
of death globally [1]. Hypertension is the major risk factor 
for CVD with a global prevalence of 26% and it is expected 
to increase by 60% by year 2025 [1]. Elevated blood pres-
sure also increases the risk of stroke or myocardial infarc-
tion by four- or two-fold, respectively. Both the escalating 
prevalence of hypertension and its sequelae are contribut-
ing to a rising global economic burden [1].
Advanced glycation end products (AGEs) may play 
an important role in the development and/or progres-
sion of CVD and specifically hypertension [2–7]. AGEs are 
a heterogeneous group of compounds that are formed by 
non-enzymatic glycation of proteins, lipids and nucleic 
acids. AGEs are known to elicit their deleterious effects 
by binding to the pro-inflammatory, cell surface bound 
receptor for AGEs (RAGE). A number of soluble forms of 
RAGE have been identified in the circulation of humans. 
Soluble RAGE (sRAGE) is thought to exist as a result of 
protealytic cleavage of RAGE from the cell surface. By con-
trast, endogenous secretary RAGE (esRAGE) is c-terminally 
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truncated splice variant of RAGE which is released from 
the cell. The soluble forms of RAGE have been identified 
as decoy receptors for RAGE as they are capable of binding 
to RAGE yet lack the c-terminus which translate the del-
eterious signaling [8, 9]. It is for this reason, that esRAGE 
and sRAGE have been proposed as possible biomarkers 
for diabetic complications and CVD. Circulating levels of 
both esRAGE and sRAGE have been shown to be associ-
ated with arterial stiffness in diabetic and hypertensive 
patients [10, 11].
The two main sources of AGEs within the body are 
exogenous dietary AGEs mostly from food processing and 
endogenous AGEs that are generated in excess by abnor-
mal glucose and lipid metabolism [2, 7, 12, 13]. We and 
others have demonstrated that the consumption of diets 
high in AGEs elicit deleterious effects throughout the body 
including: increased inflammation [14, 15] driving insulin 
resistance [16] and impairing renal function [14, 17, 18].
Experimental evidence has shown that AGE accumu-
lation affords structural and functional changes in the car-
diovascular system and results in myocardial relaxation 
abnormalities, atherosclerotic plaque formation, large 
artery stiffening and endothelial dysfunction [4, 19–22]. In 
the vessel wall, AGEs form covalent crosslinks with matrix 
proteins, which increases vessel rigidity, trap lipopro-
teins within the arterial wall and disrupts their clearance 
[23–25]. Increased circulating AGE levels and increased 
vascular tissue AGE deposition have been reported to be 
associated with impaired endothelium dependent and 
endothelium-independent vasodilatation and increased 
arterial stiffness in patients with diabetes [26, 27]. The 
latter action would be expected to elevate pulse pressure. 
Importantly, these effects have been reversed using AGE 
lowering therapies [26] suggesting that AGEs may play 
a role in the pathophysiology of hypertension. To our 
knowledge, there are no studies demonstrating the rela-
tionship between AGEs and blood pressure or develop-
ment of hypertension in healthy non-diabetic individuals.
Chronic low-grade activation of the immune system 
(CLAIS) has been identified as an important determinant 
of a number of chronic diseases including atherosclerosis 
and CVD [28, 29]. Moreover, CLAIS has been associated 
with risk factors of CVD such as glucose intolerance/dia-
betes [30], dyslipidemia [31–33] and hypertension [34, 35]. 
The relationship between CLAIS and hypertension is 
likely due to both direct AGE deposition in the vascula-
ture which contributes to arterial stiffening as well as 
impaired capacity of the endothelium to generate vasodi-
lating factors [34, 36]. The nuclear factor-kappa B (NF-κB) 
pathway is considered to be a major intracellular inflam-
matory pathway which is also known to mediate many of 
the vascular inflammatory processes [34, 36, 37]. AGEs are 
thought to activate the NF-κB pathway primarily as a result 
of their ligation with their pro-inflammatory full-length 
cell surface receptor RAGE [34, 38–41]. The relationship 
between AGEs, NF-κB in peripheral blood mononuclear 
cells (PBMC) and blood pressure has not been previously 
investigated in healthy humans.
We hypothesized that plasma AGE levels, their recep-
tors and NF-κB activity in PBMC will be associated with 
blood pressure and other cardiovascular risk factors in 
a group of healthy young normotensive non-diabetic 
individuals.
Materials and methods
Study participants and design
Forty-four non-diabetic, non-hypertensive volunteers (17 female, 
27 males) between 18 and 50 years of age participated in the study. 
Participants were non-smokers at the time of the study, generally 
healthy according to a detailed physical examination and routine 
blood analyses. No participant had signs of acute or chronic infec-
tion, or took any medication or illicit drugs. All participants under-
went a medical screening, which included a history, physical ex-
amination with anthropometric measurement and basic laboratory 
tests including fasting plasma lipid levels, liver function tests, urea, 
creatinine and electrolytes as well as a 75 g glucose load oral glucose 
tolerance test (OGTT).
The protocol was approved by the Alfred Hospital Ethics Com-
mittee and complied with the Declaration of Helsinki. All partici-
pants provided written informed consent prior to participation.
Anthropometric data
Height and weight were measured and body mass index (BMI) calcu-
lated. Waist and hip circumferences were measured and waist-to-hip 
ratio (WHR) calculated as an index of body fat distribution. Seated 
brachial blood pressure was measured three times, separated by 
1 min using a Dinamap monitor (Model 1846SX, Critikon, Tampa, FL, 
USA) after 15 min of rest. The mean of the three measurements taken 
was calculated and reported. Pulse pressure was calculated as a dif-
ference between systolic and diastolic mean blood pressure. Mean 
arterial pressure (MAP) was estimated as diastolic blood pressure + 
pulse pressure/3.
Blood analyses
Various inflammatory markers, circulating AGE parameters, glucose 
(during OGTT) and lipid levels were measured in plasma collected 
following a 12-h overnight fast. Glucose tolerance status was deter-
mined by WHO 1999 criteria [42]. Prior to these measurements, par-
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ticipants were asked to abstain from strenuous exercise and caffeine 
for 3 days. Blood samples were drawn using standard phlebotomy 
techniques into sodium citrate Vacutainers. The tubes were centri-
fuged immediately (1500 × g, 15 min, 4°C), and the plasma stored 
at −80°C until analyses were performed. Lipids were measured by 
standard laboratory assays on the Abbott Archicentre ci162000 by 
Alfred Pathology laboratory. Plasma glucose concentrations were 
measured using the glucose oxidase method (ELM 105, Radiometer 
Copenhagen, Denmark). Plasma high sensitivity CRP was measured 
by an immunotubidimetric assay (Abbott Archicentre ci162000). 
White blood cell counts (WBC) were measured by Beckman Coul-
ter LH 785 analyzer by Alfred Pathology Services. Circulating AGE 
(CML) concentrations were determined using an indirect ELISA as 
previously described [43, 44]. sRAGE was analyzed in serum samples 
using a human sRAGE sandwich ELISA (R&D Systems, Minneapo-
lis, MN, USA). esRAGE was measured in plasma by ELISA (B-bridge 
International, USA). Interleukin-6 (IL-6) and Monocyte Chemotactic 
Protein-1 (MCP-1) were measured in serum samples with high sensi-
tivity sandwich ELISA according to manufacturer’s instructions (R&D 
Systems). PBMC were isolated from whole blood by Ficol-paque den-
sity centrifugation (Amersham Biosciences, Uppsala, Sweden) as 
previously described [44, 45]. Briefly, PBMC samples were washed in 
excess PBS to remove residual FBS and DMSO. The supernatant was 
discarded and the pellets resuspended in 100 μL of triple detergent 
lysis buffer (50 mM Tris HCl pH 8.0; 150 mM NaCl; 0.02% NaN3; 0.1% 
SDS; 100 μg/mL PMSF; 1 μg/mL aprotinin; 1% nonidet P-40; 0.5% 
sodium deoxycholate, in milliQ H2O). These were sonicated and then 
centrifuged. The resulting whole cell lysate was used in the NF-κB as-
say. The protein concentration of all protein isolates was determined 
using the Pierce Bicinchoninic Acid protein assay (Pierce, Rochford, 
IL, USA) performed according to manufacturer’s instructions. The 
TransAM NF-κB DNA-binding activity assay (Active Motif, Carlsbad, 
CA, USA) was used to detect and quantify NF-κB factor activation, 
using a p65 NF-κB consensus sequence in labeled DNA in a 96-well 
plate format. Results are expressed as nanogram (ng) DNA bound 
p65 activity per μg protein.
Statistical analyses
Statistical analyses were performed using SAS Jump Statistics Soft-
ware (Cary, NC, USA). Results are reported as mean ± SD or median 
with interquartile range. Some of the variables were logarithmically 
transformed (Log10) to approximate normal distribution. Correla-
tions were performed using the Pearson correlation coefficient with 
Bonferroni correction. Multiple regression was used to assess the de-
terminants of blood pressure variables after adjusting for co-variates. 
Statistical significance was assumed when p < 0.05.
Results
Participant characteristics
The anthropometric and metabolic characteristics of the 
study population are summarized in Table 1. All partici-
pants were healthy according to the physical examina-
tion. Specifically, they were normotensive, had normal 
full blood counts, liver function tests, plasma hsCRP 
and renal function and some of them were overweight or 
obese (Table 1, liver and renal function data not shown). 
Females had lower body weight, WHR, systolic blood 
Table 1 Anthropometric, metabolic and inflammation parameters of study population.
All, n = 44 Female, n = 17 Male, n = 27
Age, years 30 ± 10 30 ± 10 31 ± 10
Weight, kg 84 ± 16 74 ± 12 90 ± 16a
BMI, kg/m2 28 ± 5 27 ± 4 29 ± 5
Waist circumference, cm 93 ± 13 87 ± 12 97 ± 14a
WHR 0.89 ± 0.08 0.83 ± 0.06 0.92 ± 0.07a
Systolic blood pressure, mm Hg 120 ± 2 114 ± 11 124 ± 11a
Diastolic blood pressure, mm Hg 74 ± 10 70 ± 9 76 ± 9
Pulse pressure, mm Hg 47 ± 8 45 ± 6 49 ± 9
MAP, mm Hg 89 ± 10 85 ± 10 91 ± 9a
Fasting glucose, mmol/L 4.8 ± 0.6 4.5 ± 0.6 4.9 ± 0.5
2 hour glucose, mmol/L 5.1 ± 1.5 5.2 ± 1.5 5.1 ± 1.5
IL-6, pg/mL 0.5 (0.3–1.0) 0.6 (0.4–0.7) 0.6 (−0.3–1.40)
hsCRP, mg/L 1.3 (0.1–2.0) 1.4 (0.5–2.2) 1.1 (0.4–1.9)
White blood cells, 109/L 6.0 ± 1.0 5.9 ± 1.0 6.0 ± 1.1
Total cholesterol, mmol/L 4.5 ± 0.8 4.4 ± 0.7 4.5 ± 0.9
HDL cholesterol, mmol/L 1.2 ± 0.3 1.4 ± 0.3 1.0 ± 0.3a
LDL cholesterol, mmol/L 2.7 ± 0.7 2.6 ± 0.6 2.8 ± 0.8
Triglycerides, mmol/L 1.3 ± 0.8 1.0 ± 0.4 1.5 ± 0.9a
Data are means  ± SD, ap < 0.05 male vs. female subjects. IL-6 and hsCRP are presented as median and interquartile range. BMI, body mass 
index; hsCRP, high sensitivity C-reactive protein; IL-6, interleukin 6; WHR, waist-hip ratio.
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pressure and MAP compared with the males but no other 
gender differences were apparent (Table 1). There were no 
differences in plasma AGE, sRAGE, esRAGE and plasma 
inflammatory parameters between males and females 
(p > 0.05).
Blood pressure, anthropometric measure-
ments, lipid and inflammation parameters
Diastolic blood pressure was related to BMI (r = 0.49, 
p < 0.001) and WHR (r = 0.46, p < 0.01). Diastolic blood pres-
sure was related to plasma triglyceride concentrations 
(r = 0.36, p < 0.05), but to none of the other plasma lipid 
parameters (data not shown).
Diastolic blood pressure was related to NF-κB activ-
ity in PBMC (Figure 1E, Table 2), WBC count (r = 0.52, 
p < 0.001), plasma IL-6 (r = 0.36, p < 0.05), MCP-1 (r = 0.40, 
p < 0.05) and hsCRP concentrations (r = 0.31, p < 0.05). 
The relationship between diastolic blood pressure and 
NF-κB activity and WBC count were independent of age, 
sex, BMI and WHR (both p < 0.05). When both NF-κB 
activity in PBMC and WBC count were placed into the 
model including age, sex, BMI and WHR, neither were 
significantly associated with diastolic blood pressure 
(p > 0.1).
Systolic blood pressure was not related to BMI or 
WHR (r = 0.27, r = 0.28 r = 0.23, respectively, p = ns). Systolic 
blood pressure was not related to any of the plasma lipid 
parameters (data not shown). Systolic blood pressure was 
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Figure 1 Interactions waist-hip ratio (WHR), between CML, NF-κB activity in PBMCs and blood pressure.
CML and BMI (A), CML and systolic blood pressure (B), CML and diastolic blood pressure (C). NF-κB activity in PBMCs and systolic blood 
pressure (D) and NF-κB activity in PBMCs and diastolic blood pressure (E).
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related to WBC count (r = 0.35, p < 0.05) but was not related 
to any other inflammation parameters (Figure 1D, other 
data not shown).
NF-κB activity was related to the pulse pressure but 
not to M MAP (Table 2). After adjustment for age, sex, BMI 
and waist, NF-κB activity approached but did not reach 
statistical significance as a determinant of pulse pressure 
(p = 0.06).
AGE parameters and anthropometric 
measures
Plasma AGEs (CML) (Figure 1A and B, Table 2) were related 
to BMI (r = −0.53, p < 0.001) and WHR (r = 0.36, p = 0.02). 
Plasma sRAGE and esRAGE concentrations were not 
related anthropometric parameters (Table 2). None of the 
AGE parameters were related to age (p > 0.1).
AGE parameters, blood pressure and lipid 
parameters
Plasma CML concentrations were inversely related to dias-
tolic (r = −0.53, p < 0.001) (Figure 1C) but not systolic blood 
pressure (r = −0.07, p = ns; Table 2). The inverse relationship 
between plasma CML concentrations and dia stolic blood 
pressure persisted after adjustment for age, sex, BMI and 
WHR (p = 0.02). Both sRAGE and esRAGE were not related 
to systolic or diastolic blood pressure (Table 2). Plasma 
CML concentrations were related to the pulse pressure 
before (Table 2) and after adjustment for age, sex, BMI 
and WHR (p = 0.02). Plasma CML concentrations were not 
related to the MAP) (Table 2).
Plasma LDL cholesterol concentrations were related 
to plasma sRAGE concentrations before (r = −0.38, p < 0.05) 
and adjustment for age and sex (p = 0.02). LDL cholesterol 
concentrations were not related to plasma CML or esRAGE 
concentrations (data not shown). Plasma esRAGE con-
centrations were related to plasma triglycerides before 
(r = −0.45, p < 0.01) and after adjustment for age, sex, BMI 
and wait/WHR (both p = 0.005).
AGE parameters and plasma inflammation 
parameters
Plasma CML concentrations were related to plasma IL-6 
(r = −0.53, p < 0.001) and MCP-1 concentrations (r = −0.55, 
p < 0.001) but not to hsCRP or WBC count (data not 
shown). sRAGE was related to plasma MCP-1 concentra-
tions whereas esRAGE was not related to any parameters 
reflecting inflammation (data not shown). None of the 
AGE parameters were related to NF-κB activity in PBMCs 
(all p > 0.1).
Multivariate analyses of CML and diastolic 
blood pressure
The plasma CML concentration was a significant determi-
nant of diastolic blood pressure independently of age, sex, 
BMI and WHR (p < 0.05). The relationship remained signif-
icant after adjustment for NF-κB activity in PBMC (p = 0.01) 
and additional adjustment for WBC count (p = 0.003). In 
the stepwise regression, plasma CML concentrations, 
WBC count and NF-κB activity in PBMC explained 52% of 
variance and were both significant determinants of dias-
tolic blood pressure.
Both plasma CML concentrations (p = 0.004) and 
NF-κB activity in PBMC (p = 0.01) were significant determi-
nants of pulse pressure after adjustment for age, sex, BMI 
and WHR.
Table 2 Pearson correlation coefficients between AGE parameters and selected cardiovascular risk factors.
CML r; p sRAGE r; p esRAGE r; p NF-κB r; p
BMI −0.55; 0.002 −0.20; 0.2 −0.17; 0.3 0.24; 0.08
WHR −0.34; 0.02 −0.22; 0.2 −0.15; 0.4 0.25; 0.1
Total cholesterol −0.15; 0.2 −0.27; 0.09 −0.15; 0.4 0.07; 0.9
Triglycerides −0.09; 0.5 −0.1; 0.6 −0.45; 0.003 0.14; 0.5
Systolic BP −0.07; 0.5 0.03; 0.7 −0.05; 0.9 0.17; 0.4
Diastolic BP −0.51; 0.001 −0.06; 0.9 −0.07; 0.9 0.47; 0.004
Pulse pressure 0.42; 0.004 0.18; 0.6 0.04; 0.6 −0.32; 0.2
MAP −0.41; 0.002 0.004; 0.8 −0.13; 0.7 0.37; 0.008
BMI, body mass index; BP, blood pressure; MAP, mean arterial pressure.
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Discussion
AGEs and the pro-inflammatory and pro-oxidant path-
ways, which they activate are likely to modulate the 
 development and progression of many chronic disease pro-
cesses including type 2 diabetes and CVD. In this present 
study, we investigated the relationship between circulating 
CML, soluble AGE-receptor concentrations, inflammation 
markers, including NF-κB activity with CVD risk factors in 
a healthy overwieight, normotensive cohort. Our findings 
demonstrate for the first time that serum CML and NF-κB 
activity in PBMCs are associated with diastolic blood pres-
sure and pulse pressure in young healthy individuals.
Chronic low-grade inflammation has been related to 
the development of hypertension [46] independently of 
adiposity [47]. In our study, we extend this evidence by 
showing that NF-κB activity in PBMC was associated with 
diastolic blood pressure in healthy normotensive individ-
uals in addition to plasma inflammation markers. This is 
consistent with results from an experimental rat model of 
hypertension, where administration of pyrrolidine dithi-
ocarbamate reduced both NF-κB activity and blood pres-
sure concurrently [48]. The NF-κB pathway is a central 
modulator of the immune system. Once activated it stimu-
lates downstream pro-inflammatory molecules as well 
as adhesion molecules [34, 38], which then induce and 
maintain inflammation within the vascular wall, stimu-
late deposition of extracellular matrix and promote hyper-
trophy and/or hyperplasia of vascular smooth muscle 
cells [49, 50].
The accumulation of AGEs over the life span may 
contribute to the development of CVD by contributing to 
arterial stiffening, endothelial dysfunction and plaque 
formation [7, 26, 36, 51–54]. There is a paucity of evidence 
from humans in this area of research. Increased levels of 
circulating AGEs have been associated with elevations in 
systolic blood pressure in people with diabetes [55] and 
in those with chronic kidney disease on hemodialysis 
[56–58]. Furthermore, administration of AGE crosslink 
breaker (ALT-711) to patients with hypertension was asso-
ciated with a concurrent reduction in AGEs, improved 
endothelial function and reduced arterial stiffness and 
pulse pressure [29]. These data bolster the evidence of 
the involvement of AGEs in hypertension as well as arte-
rial stiffening [29, 59–61]. We showed for the first time 
that higher circulating levels of CML were associated with 
lower diastolic blood pressure and higher pulse pressure 
in young healthy normotensive individuals. This suggests 
that circulating AGE levels are associated with aortic stiff-
ening in individuals without known cardiovascular risk 
factors. Crosslinking AGEs have been shown to induce 
aortic stiffening in an experimental model of diabetes [62]. 
Consistent with this, we have also previously shown that 
low CML levels are associated with abdominal aortic aneu-
rysms in patients with type 2 diabetes [63]. As the aorta 
stiffens with aging, pulse pressure increases and dias-
tolic pressure decreases. The decrease in diastolic blood 
pressure then compromises the coronary circulation and 
furthermore contributes to ischemic heart disease and 
cardiovascular events [64, 65]. As CML within the arterial 
extracellular matrix was not measured, it is not possible 
to establish whether this mechanism contributed to aortic 
stiffening via crosslinking.
The soluble receptors for AGEs are considered to 
act as decoy receptors to prevent the pro-inflammatory 
interaction of AGEs with their cell-surface full length 
receptor RAGE [13, 66, 67]. In older community dwelling 
women, both esRAGE and sRAGE were found to be pre-
dictive of CVD mortality [68]. In a cross-sectional analy-
sis of hypertensive patients, serum sRAGE correlated 
with systolic blood pressure [69]. In addition, sRAGE and 
esRAGE were associated with carotid atherosclerosis in 
hemodialysis patients [70, 71]. In diabetic patients with 
coronary artery disease, sRAGE has been shown to cor-
relate with diastolic blood pressure [72]. In the present 
study, we found no correlation between blood pressure 
and the levels of soluble AGE receptors, sRAGE and 
esRAGE. This could be due to differences in our study 
population, which was younger, overweight, normoten-
sive, non-diabetic and had normal renal function. In our 
study, plasma LDL cholesterol and triglyceride levels 
were correlated with sRAGE and esRAGE, respectively, 
whilst no association was found with CML. This is con-
sistent with data in patients with diabetes and coronary 
artery disease, where sRAGE correlated with LDL choles-
terol and triglycerides [72].
We and others have shown that plasma AGEs are 
related to adiposity [14, 73–75]. In the present study, we 
confirm these findings by showing the negative  association 
between circulating levels of CML and various measures of 
adiposity. The direction of this relationship is  surprising 
given that it is likely that obese individuals would consume 
more dietary AGEs compared to lean individuals. In addi-
tion, a short-term low calorie diet intervention reduced 
serum AGEs in healthy overweight or obese adults [76]. It 
has been proposed that the inverse cross-sectional rela-
tionship between circulating AGEs and  adiposity may 
be a direct result of AGEs preferentially depositing in the 
adipose tissue as opposed to the  circulation. This could be 
due to the fact that adipocytes are known to express CD36, 
a scavenger receptor that binds AGEs and facilitates endo-
cytosis and degradation of AGEs [75].
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In the present study, we showed that plasma AGEs 
levels and NF-κB activity in PBMC were related to diastolic 
blood pressure and pulse pressure independent of obesity. 
This may relate in part to AGEs promoting stiffening of 
the aorta. Furthermore, AGEs in the vascular tissue may 
induce these deleterious vascular effects is by impairing 
nitric oxide synthase activity in endothelial cells as has 
been previously described [36, 77, 78]. As noted previously, 
AGEs are thought to activate the NF-κB pathway primarily 
as a result of their ligation with RAGE. This subsequently 
induces the activation of a number of NF-κB mediated pro-
inflammatory pathways, generation of reactive oxygen 
species and increased expression of adhesion molecule 
which then promote atherosclerosis further contributing 
to arterial stiffening [38, 41, 79].
Limitations
First, the cross-sectional nature of the study cannot delin-
eate the cause-and-effect relationships among plasma 
CML, NF-κB activity and diastolic blood pressure. Second, 
the sample size is relatively small, and hence, the results 
should be interpreted with caution. However, the strength 
of the correlations and their robustness in various adjusted 
models attest to the validity of the major findings.
In conclusion, we have demonstrated that plasma 
CML and NF-κB activity in PBMC are both important 
determinants of diastolic and pulse pressure in a healthy 
non-diabetic normotensive population. Further investiga-
tion is warranted to determine the mechanisms by which 
changes in AGEs and NF-κB may contribute to the devel-
opment of aortic stiffening in humans.
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